Presentation of 1-year IVAN and 2-year CATT study results

April 18th, 2012
Rockville, Md.: ARVO is pleased to host a presentation of the one-year results from the U.K.'s Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) study and the two-year results of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) trial.

These two multicenter randomized clinical trials, sponsored by the National Institute of Health Research in the United Kingdom and the National Eye Institute, respectively, evaluate the relative efficacy and safety of Lucentis and Avastin in the management of neovascular age-related macular degeneration (AMD).

The presentation will also live-streamed at http://prolibraries.com/arvo/registration/event. While annual meeting registration is required for the session in Fort Lauderdale, the online is event is free.

The 2012 ARVO Annual Meeting, Translational Research: Seeing the Possibilities, takes place May 6 – 10 in Fort Lauderdale, Fla. Registration information can be found at www.arvo.org/am.

Provided by Association for Research in Vision and Ophthalmology

This Phys.org Science News Wire page contains a press release issued by an organization mentioned above and is provided to you “as is” with little or no review from Phys.Org staff.

More news stories

Phthalates heighten risk for childhood asthma

Researchers at the Columbia Center for Children's Environmental Health at the Mailman School of Public Health are the first to demonstrate an association between childhood asthma and prenatal exposure to two phthalates used ...

Physicists design zero-friction quantum engine

(Phys.org) —In real physical processes, some energy is always lost any time work is produced. The lost energy almost always occurs due to friction, especially in processes that involve mechanical motion. ...